In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported no serious complications after COVID-19 vaccination. Almost all participants received the Pfizer COVID-19 vaccine. The Centers for Disease Control and Prevention recommends COVID-19 vaccination for patients with a history of MIS-C, a rare and potentially fatal immune reaction to SARS-CoV-2 infection. According to CDC data, over 9,000 U.S. patients have been diagnosed with MIS-C, which appears to be on the decline.
 
“A big part of that decline is that COVID vaccination has been protective against this rare condition in those who have received it,” said Audrey Dionne, M.D., a pediatric cardiologist at Boston Children’s Hospital who served as co-leader for the study, funded by the National Institutes of Health.

Related News Articles

Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The National Institutes of Health Sept. 16 announced it has launched a consortium to help reduce preventable stillbirths across the U.S. The NIH said…
Headline
A blog by Julia Resnick, AHA senior director of health outcomes and care transformation, describes a new project with the Commonwealth Fund that will explore…